DexCom is no longer the sole competitor in manufacturing glucose monitoring systems, J.P. Morgan said. With new, low-priced competition, the firm says DexCom now must innovate under pressure to discount its hardware, which previously made margins of 45 to 50 percent per device. But all is not lost for DexCom, as J.P. Morgan says its “technology is superior to Libre.”
“Before long, DexCom should be able to surpass the Libre offering,” J.P. Morgan said. “But it will be at a lower price point and likely less attractive economics than we’ve all been expecting.”
The technology still has a distance to go before widespread adoption, according to J.P. Morgan, but continuous glucose monitoring is headed toward becoming the standard for monitoring Type 1 diabetics. The firm warned in closing that DexCom’s lead in the market is now smaller.
“In a remarkably short period of time, in Europe and now other markets outside the US, Abbott has seized the lead from Dexcom, winning multiple regulatory and reimbursement approvals and building a $450 million market for Libre seemingly overnight,” J.P. Morgan added.